Trial Profile

A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients With Advanced or Recurrent, Non-resectable HPV 16-Positive Cervical Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; VB10.16 (Primary)
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Nykode Therapeutics

Most Recent Events

08 Jan 2025 Results presented in the Nykode Therapeutics Media Release.
08 Jan 2025 According to a Nykode Therapeutics media release, Final data from the Phase 2 VB-C-02 trial were published in the peer-reviewed BMJ Journal for ImmunoTherapy of Cancer.
22 Mar 2024 According to a Nykode Therapeutics media release, will present detailed data in a future scientific publication and at a forthcoming conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com